Airain LTD Has Increased Nxstage Medical (NXTM) Holding By $302,640; 5 Analysts Bullish Progenics Pharmaceuticals, Inc. (PGNX)

September 17, 2017 - By Michael Collier

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 10 analyst reports since August 6, 2015 according to SRatingsIntel. The company was upgraded on Friday, October 23 by Jefferies. On Thursday, October 27 the stock rating was initiated by Aegis Capital with “Buy”. The rating was upgraded by Needham on Monday, February 6 to “Strong Buy”. Cantor Fitzgerald maintained the shares of PGNX in report on Wednesday, August 9 with “Buy” rating. On Thursday, June 8 the stock rating was maintained by Jefferies with “Buy”. The company was maintained on Thursday, August 6 by Brean Capital. The stock has “Buy” rating by Needham on Friday, August 7. Zacks downgraded the shares of PGNX in report on Friday, August 7 to “Buy” rating. The rating was maintained by Needham on Tuesday, June 20 with “Buy”. See Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) latest ratings:

09/08/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $15.0000 Maintain
12/07/2017 Broker: Cantor Fitzgerald Rating: Overweight New Target: $15 Initiates Coverage On
20/06/2017 Broker: Needham Rating: Buy Maintain
08/06/2017 Broker: Jefferies Rating: Buy New Target: $12.0000 Maintain

Airain Ltd increased Nxstage Medical Inc (NXTM) stake by 95.76% reported in 2016Q4 SEC filing. Airain Ltd acquired 11,640 shares as Nxstage Medical Inc (NXTM)’s stock declined 27.12%. The Airain Ltd holds 23,796 shares with $624,000 value, up from 12,156 last quarter. Nxstage Medical Inc now has $1.83 billion valuation. The stock decreased 0.22% or $0.06 on September 15, reaching $27.79. About 983,106 shares traded. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 21.18% since September 17, 2016 and is uptrending. It has outperformed by 4.48% the S&P500.

The stock increased 2.41% or $0.15 on September 15, reaching $6.37. About 1.76M shares traded or 33.33% up from the average. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since September 17, 2016 and is uptrending. It has outperformed by 31.71% the S&P500.

Investors sentiment decreased to 1.29 in 2016 Q4. Its down 0.76, from 2.05 in 2016Q3. It dropped, as 12 investors sold Progenics Pharmaceuticals, Inc. shares while 38 reduced holdings. 31 funds opened positions while 30 raised stakes. 59.59 million shares or 0.65% more from 59.20 million shares in 2016Q3 were reported. 79,028 are owned by Fisher Asset Mgmt Ltd Liability. 639 were accumulated by Meeder Asset Mngmt. Blackrock Incorporated invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Creative Planning holds 0% or 15,200 shares in its portfolio. Eagle Asset Mgmt has invested 0.15% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Pacad Invest reported 0.04% stake. Principal Financial Grp Inc invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Walleye Trading Ltd Liability Corporation stated it has 8,000 shares or 0% of all its holdings. Baker Bros Lp holds 3.15M shares or 0.27% of its portfolio. Mufg Americas Hldg stated it has 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Millennium Management Lc owns 334,670 shares for 0.01% of their portfolio. Tiaa Cref Investment Mngmt Ltd Llc accumulated 0% or 202,438 shares. Fuller Thaler Asset holds 448,000 shares or 0.06% of its portfolio. Allianz Asset Management Ag holds 211,010 shares or 0% of its portfolio. Family Mgmt holds 0.06% or 10,000 shares.

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The company has market cap of $447.62 million. The Company’s pipeline includes therapeutic agents designed to target cancer ; prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It currently has negative earnings. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation.

Among 9 analysts covering NxStage Medical (NASDAQ:NXTM), 2 have Buy rating, 1 Sell and 6 Hold. Therefore 22% are positive. NxStage Medical had 16 analyst reports since November 4, 2015 according to SRatingsIntel. BTIG Research initiated NxStage Medical, Inc. (NASDAQ:NXTM) rating on Friday, December 18. BTIG Research has “Buy” rating and $27 target. On Monday, August 7 the stock rating was downgraded by Canaccord Genuity to “Hold”. Jefferies downgraded the shares of NXTM in report on Tuesday, August 8 to “Hold” rating. Canaccord Genuity maintained NxStage Medical, Inc. (NASDAQ:NXTM) on Tuesday, August 2 with “Buy” rating. The rating was maintained by BTIG Research with “Buy” on Tuesday, June 6. The stock has “Buy” rating by Sterne Agee CRT on Friday, December 11. The rating was maintained by Northland Capital on Monday, August 7 with “Hold”. On Friday, August 11 the stock rating was downgraded by BTIG Research to “Neutral”. The stock of NxStage Medical, Inc. (NASDAQ:NXTM) has “Outperform” rating given on Tuesday, June 28 by Northland Capital. The stock has “Hold” rating by Craig Hallum on Monday, August 7.

Airain Ltd decreased Booz Allen Hamilton Holding Corp (NYSE:BAH) stake by 9,025 shares to 7,445 valued at $269,000 in 2016Q4. It also reduced Raytheon Co (NYSE:RTN) stake by 10,897 shares and now owns 32,809 shares. Avery Dennison Corp (NYSE:AVY) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com